L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental

Jose Luis Ordoñez-Librado1, Veronica Anaya-Martinez, Ana Luisa Gutierrez-Valdez

  • 1Laboratorio de Neuromorfologia, FES Iztacala, UNAM, Av. de los Barrios 1, Tlalnepantla 54090, Mexico.

Neuroscience Letters
|January 19, 2010
PubMed

Insights

Manganese inhalation caused motor deficits in mice by decreasing dopamine. L-DOPA treatment reversed these Parkinson-like symptoms, suggesting manganese neurotoxicity impacts dopaminergic pathways.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pharmacology

Background:

  • Manganese (Mn) exposure is linked to neurological disorders.
  • Dopaminergic system dysfunction is implicated in motor control deficits.

Purpose of the Study:

  • To investigate if L-DOPA can ameliorate motor impairments caused by manganese inhalation.
  • To confirm the dopaminergic origin of manganese-induced motor alterations.

Main Methods:

  • Mice inhaled a manganese chloride and manganese acetate mixture for 5 months.
  • Motor function tests were conducted weekly.
  • Dopamine levels were measured, and L-DOPA treatment was administered to a subset of mice.

Main Results:

  • Manganese inhalation significantly decreased striatal dopamine by 71%.
  • Mice exhibited akinesia, postural instability, and tremor.
  • L-DOPA treatment successfully reverted these motor deficits.

Conclusions:

  • Inhaled manganese mixture induces motor impairments related to nigrostriatal dopaminergic dysfunction.
  • L-DOPA effectively reverses manganese-induced motor deficits.
  • This study provides a potential Parkinson's disease experimental model for understanding manganese neurotoxicity.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...